175 related articles for article (PubMed ID: 34366628)
1. Y-box binding protein 1 augments sorafenib resistance
Liu T; Xie XL; Zhou X; Chen SX; Wang YJ; Shi LP; Chen SJ; Wang YJ; Wang SL; Zhang JN; Dou SY; Jiang XY; Cui RL; Jiang HQ
World J Gastroenterol; 2021 Jul; 27(28):4667-4686. PubMed ID: 34366628
[TBL] [Abstract][Full Text] [Related]
2. Dietary antioxidant quercetin overcomes the acquired resistance of Sorafenib in Sorafenib-resistant hepatocellular carcinoma cells through epidermal growth factor receptor signaling inactivation.
Zhang Z; Wu H; Zhang Y; Shen C; Zhou F
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):559-574. PubMed ID: 37490119
[TBL] [Abstract][Full Text] [Related]
3. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
Deng L; Sun J; Chen X; Liu L; Wu D
J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma.
Seo SH; Cho KJ; Park HJ; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Cheon JH; Yook JI; Kim MD; Joo DJ; Kim SU
Cell Commun Signal; 2023 Nov; 21(1):339. PubMed ID: 38012711
[TBL] [Abstract][Full Text] [Related]
5. Family with sequence similarity 111 member B contributes to tumor growth and metastasis by mediating cell proliferation, invasion, and EMT via transforming acidic coiled-coil protein 3/PI3K/AKT signaling pathway in hepatocellular carcinoma.
Yang Y; Yan Z; Jiao Y; Yang W; Cui Q; Chen S
Environ Toxicol; 2024 Jan; 39(1):409-420. PubMed ID: 37782700
[TBL] [Abstract][Full Text] [Related]
6. EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy.
Xia H; Dai X; Yu H; Zhou S; Fan Z; Wei G; Tang Q; Gong Q; Bi F
Cell Death Dis; 2018 Feb; 9(3):269. PubMed ID: 29449645
[TBL] [Abstract][Full Text] [Related]
7. Gas7 attenuates hepatocellular carcinoma progression and chemoresistance through the PI3K/Akt signaling pathway.
Liu WF; Zhang QW; Quan B; Zhang F; Li M; Lu SX; Dong L; Yin X; Liu BB
Cell Signal; 2023 Dec; 112():110908. PubMed ID: 37769891
[TBL] [Abstract][Full Text] [Related]
8. IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis.
Chen J; Sun S; Li H; Cai X; Wan C
Front Immunol; 2024; 15():1373321. PubMed ID: 38596684
[TBL] [Abstract][Full Text] [Related]
9. Physalin A Induces Apoptosis and Autophagy in Hepatocellular Carcinoma via Inhibition of PI3K/Akt Signaling Pathway.
Shang X; Chen Z; Liu J; Xu S; Li L; Yang Z; Cui Y; Ruan P; Peng X
Biochem Genet; 2024 Apr; 62(2):633-644. PubMed ID: 37400742
[TBL] [Abstract][Full Text] [Related]
10. A novel polypeptide encoded by the circular RNA ZKSCAN1 suppresses HCC via degradation of mTOR.
Song R; Ma S; Xu J; Ren X; Guo P; Liu H; Li P; Yin F; Liu M; Wang Q; Yu L; Liu J; Duan B; Rahman NA; Wołczyński S; Li G; Li X
Mol Cancer; 2023 Jan; 22(1):16. PubMed ID: 36691031
[TBL] [Abstract][Full Text] [Related]
11. Artesunate Sensitizes human hepatocellular carcinoma to sorafenib via exacerbating AFAP1L2-SRC-FUNDC1 axis-dependent mitophagy.
Ma Z; Chen W; Liu Y; Yu L; Mao X; Guo X; Jiang F; Guo Q; Lin N; Zhang Y
Autophagy; 2024 Mar; 20(3):541-556. PubMed ID: 37733919
[TBL] [Abstract][Full Text] [Related]
12. RHNO1 disruption inhibits cell proliferation and induces mitochondrial apoptosis via PI3K/Akt pathway in hepatocellular carcinoma.
Du D; Wang S; Li T; Liu Z; Yang M; Sun L; Yuan S
Biochem Biophys Res Commun; 2023 Sep; 673():96-105. PubMed ID: 37364391
[TBL] [Abstract][Full Text] [Related]
13. MEX3A determines in vivo hepatocellular carcinoma progression and induces resistance to sorafenib in a Hippo-dependent way.
Fang S; Zheng L; Chen X; Guo X; Ding Y; Ma J; Ding J; Chen W; Yang Y; Chen M; Zhao Z; Tu J; Ji J
Hepatol Int; 2023 Dec; 17(6):1500-1518. PubMed ID: 37460832
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of HCG18 in the sorafenib resistance of hepatocellular carcinoma.
Li H; Hu J; Qiu L; Wu Y; Zhong B; Ye R; Xie B
Anticancer Drugs; 2024 Jan; 35(1):55-62. PubMed ID: 37823256
[TBL] [Abstract][Full Text] [Related]
15. Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1.
Zhao J; Lin E; Bai Z; Jia Y; Wang B; Dai Y; Zhuo W; Zeng G; Liu X; Cai C; Li P; Zou B; Li J
BMC Cancer; 2023 Dec; 23(1):1198. PubMed ID: 38057830
[TBL] [Abstract][Full Text] [Related]
16. [Baicalin induces ferroptosis in HepG2 cells by inhibiting ROS-mediated PI3K/Akt/FoxO3a signaling pathway].
Zhou JQ; Li HJ; Zeng YH; Chen HH; Liang WY; Zhang J; Ding FP
Zhongguo Zhong Yao Za Zhi; 2024 Mar; 49(5):1327-1334. PubMed ID: 38621980
[TBL] [Abstract][Full Text] [Related]
17. The regulation of proliferation and apoptosis in hepatocellular carcinoma via insulin-like growth factor 1 receptor.
Xu G; Chu J; Shi Y; Huang L; Fu J
Growth Horm IGF Res; 2022 Oct; 66():101499. PubMed ID: 36084573
[TBL] [Abstract][Full Text] [Related]
18. Lianhua Qingwen exerts anti-liver cancer effects and synergistic efficacy with sorafenib through PI3K/AKT pathway: Integrating network pharmacology, molecular docking, and experimental validation.
Wei J; Zhao X; Long F; Tian K; Wu L
Gene; 2024 Jun; 912():148383. PubMed ID: 38493972
[TBL] [Abstract][Full Text] [Related]
19. Exploring the molecular mechanism of Artemisia rupestris L. for the treatment of hepatocellular carcinoma via PI3K/AKT pathway.
Zhang S; Cai X; Khan GJ; Cheng J; He J; Zhai K; Mao Y
J Ethnopharmacol; 2024 Mar; 322():117572. PubMed ID: 38097024
[TBL] [Abstract][Full Text] [Related]
20. ATRA sensitized the response of hepatocellular carcinoma to Sorafenib by downregulation of p21-activated kinase 1.
Wang K; Qiu X; Zhang Z; Xu H; Tan Y; Su R; Gao F; Zhuo J; Li W; Lian Z; He H; Xu X
Cell Commun Signal; 2023 Aug; 21(1):193. PubMed ID: 37537668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
